Grand Pharmaceutical Group Ltd.
Industry Group: Pharmaceuticals
Country/Region: Hong Kong
Identifier: HKG:512
Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from the PRC and also has a presence in America; Europe; Asia other than the PRC and others.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 532 out of 850
Universe
Global Universe 11142 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Grand Pharmaceutical Group Ltd. |
31
High
|
532 out of 850 |
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. |
33
High
|
610 out of 850 |
RemeGen Co., Ltd. |
35.6
High
|
707 out of 850 |
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. |
36
High
|
726 out of 850 |
Chongqing Taiji Industry (Group) Co., Ltd. |
42.7
Severe
|
843 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Grand Pharmaceutical Group Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Grand Pharmaceutical Group Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Grand Pharmaceutical Group Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level